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Summary Immunotoxins that carry two toxin molecules to the target cell should in theory have a greater anti-tumour effect than those that
carry just one. We have investigated the therapeutic efficacy of two anti-CD7-saporin immunotoxins constructed with one saporin (HB2-Sap
1-mer) or two saporin molecules (HB2-Sap 2-mer) per immunotoxin molecule. In vitro, the 2-mer immunotoxin was 5.6 times more effective
than the 1 -mer immunotoxin at inhibiting protein synthesis in the CD7+ human T-cell acute lymphoblastic leukaemia (T-ALL) cell line HSB-2
and was also more effective at inhibiting HSB-2 cell proliferation. Flow cytometry revealed that the 2-mer immunotoxin had a reduced binding
capacity to HSB-2 cells compared with the 1-mer immunotoxin or native HB2 antibody. In therapy studies in SCID mice with disseminated
HSB-2 human leukaemia, the 2-mer immunotoxin performed marginally better than the 1-mer immunotoxin, but log-rank analysis did not
reveal any significant differences between the two therapy groups. We therefore conclude that, although the 2-mer immunotoxin performed
better than the 1 -mer immunotoxin against target HSB-2 cells in vitro, this improved performance was not reflected as an improved in vivo
therapeutic outcome in the SCID mouse model.
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Immunotoxins (ITs) have promising potential as therapeutic
agents for cancer, particularly in the treatment of leukaemias and
lymphomas, in which they have been shown to have marked activ-
ities (Vitetta et al, 1991; Falini et al, 1992; Amlot et al, 1993;
Grossbard et al, 1993). Comprising a monoclonal antibody
component linked to a toxin orribosome-inactivating protein (rip),
such as ricin A chain or saporin, immunotoxins selectively deliver
the toxin moiety only to cell populations expressing the target
antigen recognized by the antibody. There are, however, a multi-
tude offactors that can effect the potency ofa given immunotoxin
for its target cell, which can severely limit its therapeutic value. At
the mechanistic level, such factors include the isotype and affinity
(van-Oosterhout et al, 1994) ofthe antibody component, the prox-
imity of the target antigen epitope to the target cell membrane
(Press et al, 1988, May et al, 1991), the expression by the target
cell of antigens unrelated to the target antigen and that probably
assist in the internalization of immunotoxin by receptor-mediated
endocytosis (van-Oosterhout et al, 1994) and, of pivotal impor-
tance, the fundamental nature of the target antigen and the ease
with which it internalizes to the appropriate intracellular compart-
ment once antibody has bound to its target ligand (May, et al.
1991, Preijers 1988, Wargalla and Reisfeld 1989). Ultimately, the
key determinants governing the therapeutic potency of any given
immunotoxin revolve around two key issues: firstly, the in vivo
accessibility of immunotoxin to the tumour and, secondly, the
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efficiency of the internalization and trafficking process which
delivers immunotoxin to the appropriate intracellular compart-
ment. The toxin component is then able to catalytically inactivate
cellular ribosome activity, leading ultimately to cell death.
Any method that improves immunotoxin potency without a
concomitant increase in toxicity would be a step forward in the
goal to achieve a better therapeutic index with this class of phar-
maceutical. We have recently shown that the use ofa combination
of two different immunotoxins, each immunotoxin (IT) recog-
nizing a different targetmolecule (CD19 and CD38) on the surface
ofthe Burkitt's lymphoma cell line Ramos, leads to a significantly
better therapeutic outcome in SCID mice than that obtained when
each IT is used individually (Flavell et al, 1995a). We speculate
that this improvement is due to two main factors; firstly,
lymphoma cells positive for both CD19 and CD38 would receive
more saporin when both molecules are simultaneously targeted;
and, secondly, cells that were negative or down-regulated for one
of the target molecules and would otherwise escape killing by a
single IT recognizing this antigen would be killed by the other IT
in the combination. Increasing the number of saporin molecules
delivered to the target cell by any individual IT would thus be one
possible route to increasing immunotoxin potency. One way of
achieving this would be to conjugate more toxin moieties per
single unit ofantibody. In the current study, we have compared the
in vitro and in vivo therapeutic efficacy ofanti-CD7 HB2-Sap ITs
constructed with one (1-mer) ortwo (2-mer) saporin molecules per
antibody molecule. We show that, while the in vitro potency ofthe
2-mer IT is substantially greater than the 1-mer IT, the in vivo
performance of the two ITs in SCID mice bearing HSB-2
leukaemia is similar. However, the toxicity of the 2-mer IT is
substantially increased.
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MATERIALS AND METHODS
SCID mice
Pathogen-free CB-17 scid/scid (SCID) mice of both sexes (6-10
weeks of age) were produced from our own breeding colony and
used in all the experimental work described here. The breeding
colony is maintained to British Home Office requirements under
sterile conditions inside a laminar flow isolator, and animals are
housed on sterile bedding and provided with sterile water and food
ad libitum. Animals for experimental use were transferred from
the isolator to autoclaved filter-top microisolator cages and housed
on sterile bedding as five single sex animals per cage. These
animals were also provided with sterile water and food ad libitum,
and all manipulations with these animals were carried out in a
laminar flow hood by personnel using aseptic techniques.
HSB-2 human T-AII cell line
The CD7+ human cell line HSB-2 was originally established from
peripheral blood leukaemic blasts from a 4-year-old paediatric
patient with terminal T-cell acute lymphoblastic leukaemia
(Adams et al, 1970). HSB-2 cells were maintained in the loga-
rithmic phase ofgrowth in culture flasks containing antibiotic-free
RPMI medium with 10% fetal calf serum and supplements of2 aM
sodium pyruvate and 2 mm glutamine (referred to as RIO medium)
at 37°C under a humidified atmosphere of5% carbon dioxide.
HB2 anti-CD7 antibody production
The anti-CD7 antibody-producing hybridoma clone HB2 was
obtained from the American Tissue Culture Collection (ATCC,
Bethesda, MD, USA). Bulk anti-CD7 antibody was produced by
inoculating 5 x 108 HB2 hybridoma cells into an Endotronics
Accusyst R hollow fibre bioreactor (Endotronics, MN, USA), as
per manufacturers instructions with some minor modifications.
Harvested antibody-containing culture supematants were concen-
trated on a Sartorius cross-flow filtration apparatus equipped with a
30 000 kDa cut-off sanitizable cellulose acetate membrane. HB2
antibody was purified to homogeneity from culture supernatants by
acombination ofammonium sulphate precipitation,anion-exchange
chromatography on DEAE-Sepharose (Sigma Chemical, Poole,
UK) and Sephacryl-S200HR (Sigma Chemical) gel filtration.
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Figure 1 Elution profile of 1-mer and 2-mer HB2-Sap ITs from CM-
sepharose with a 0-300 mm sodium chloride gradient
Purified antibody gave a single band of 160 000 Da on SDS-PAGE
analysis undernon-reducing conditions and retained full immunore-
activity as demonstrated by flow cytometry.
Saporin production
Seeds of the Soapwort plant Saponaria officinalis were kindly
supplied by Chiltern Seeds, Ulverston, Cumbria, UK. The S06
isoform ofsaporin was extracted from seeds as describedpreviously
(Stirpe etal, 1983) andpurified to homogeneity by acombination of
cation-exchange chromatography on carboxymethyl-Sepharose and
gel filtration on Sephacryl-S200HR. The final product gave a single
band of 29 500 Da on SDS-PAGE and was immunoreactive on
ELISA with both polyclonal and monoclonal anti-saporin antisera.
Construction of 1-mer and 2-mer HB2-Sap
immunotoxins
Saporin was coupled to intact HB2 antibody using the heterobi-
functional cross-linking agent N-succinimidyl 3-(2-pyridyldithio)
propionate (SPDP), as described previously (Thorpe et al, 1985).
The immunotoxin HB2-Sap produced by this procedure comprises
a mixture of free HB2 antibody; 1-mer IT comprised one saporin
molecule per antibody molecule and 2-mer IT comprised two
saporin molecules per antibody molecule and a trace amount of 3-
mer IT. Each ofthese components were separated from each other
by carboxymethyl-Sepharose cation-exchange chromatography in
5 mm phosphate buffer (pH 6.5), as described previously (Lambert
et al, 1983) but using a custom-designed and optimized semi-step-
wise linearelution gradient ofsodium chloride. Briefly, the bulk of
the free HB2 antibody was eluted from the column with a linear
gradient of 60-80 mm sodium chloride; the 1-mer IT was eluted
between 80 and 105 mm and the 2-merIT as a single peak between
105 and 180 mm (see Figure 1). The l-mer and 2-mer ITs obtained
were dialysed into phosphate-buffered saline (PBS) (pH 7.2) and
filter sterilized by passage through a 0.2-mm pyrogen-free filter.
Concentrations of the individual immunotoxin species were esti-
mated spectrophotometrically at 280 nm and reported as total
protein content expressed as a molarconcentration, without taking
into account any contaminating species.
Sodium dodecyl polyacrylamide gel electrophoresis
(SDS-PAGE) analysis of 1-mer and 2-mer immunotoxins
300 SDS-PAGE analysis, according to the method of Laemmli (1970)
was used to confirm purity of antibody, saporin and immuno-
200 toxins. Five per cent non-reducing SDS-PAGE gels with 3%
,,, stacking gels were routinely used for separations. An aliqnot of
°. 20 [tg of each sample in non-reducing sample buffer was loaded c
3 into each track. Following electophoresis, gels were stained with 0
=- Coomassie blue, scanned on a Canon IX 4015 flatbed scanner
c- using TWAIN compatible software, and band densities were
3 analysed using the Sigmagel software package (Jandel Scientific
Software, Erkrath,Germany).
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Binding of 1-mer and 2-mer immunotoxins to HSB-2 cells
0
The binding of HB2-Sap 1-mer and HB2-Sap 2-mer immuno-
toxins to HSB-2 cells was confirmed and compared with that
obtained for the native HB2 antibody by flow cytometry. One
million HSB-2 cells were incubated with three different molar
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concentrations (62.5 nM 6.25 nM and 0.625 nM) of each immuno-
toxin or native HB2 antibody diluted in phosphate-buffered saline
pH 7.2 for 30 min at 4°C in the presence of 0.1% sodium azide.
Negative control cells were incubated with an irrelevant isotype-
matched control antibody (BU-12 anti-CD19) at the appropriate
concentration. Cells were washed twice in cold phosphate-
buffered saline containing 0.1% sodium azide, and the cell pellets
were incubated for a further 30 min in 100 tl of FITC-labelled
Fab2 rabbit anti-mouse immunoglobulins (Sigma Chemical)
diluted 1:20 in PBS. Cells were washed twice in PBS and then
resuspended in cold PBS. Surface fluorescence was quantified on
a Coulter Epics XL flow cytometer equipped with XL analytical
software. In competitive inhibition studies, one million HSB-2
cells were incubated for 30 min at 4°C with FITC-labelled HB2
antibody at a concentration of25 FLM together with HB2-Sap 1-mer
or 2-mer as competitor at molar concentrations of 250 liM, 25 FtM
and 2.5 [tM in the presence of 0.1% sodium azide. Cells were
washed twice in cold PBS containing azide, and surface fluores-
cence was again quantified using flow cytometry.
Protein synthesis inhibition assay
The ability of HB2-Sap 1-mer or 2-mer immunotoxins to inhibit
protein synthesis in the HSB-2 target cell line was evaluated using
a [3H]leucine uptake assay described by us previously (Flavell et
al, 1991). Briefly, triplicate cultures of 1 x 105 target HSB-2 cells
were exposed to individual equimolar concentrations ofeach IT or
saporin in RIO medium and incubated at 370C for48 h in a humid-
ified atmosphere of5% carbon dioxide 95% air. Afterthis period of
time, 1 ,uCi of [3H]leucine was added to each culture and incuba-
tion continued for a further 14-16 h. Cells were harvested onto
glass fibre discs using a Skatron cell harvester, and individual discs
were counted forradioactivity on a Packard scintillation counter.
In experiments undertaken to quantify the amount of native
HB2 antibody required to block the cytotoxicity of 1-mer and 2-
mer ITs,triplicate cultures of 1 x 105 HSB-2 cells were exposed for
48 h to a fixed 0.1 nm concentration of the 1-mer or 2-mer IT
together with increasing molar concentrations ofnative HB2 anti-
body and processed exactly as described above.
For kinetic studies, triplicate cultures of HSB-2 cells were
exposed to five different molar concentrations of 1-mer or 2-mer
IT (1 pM-I0 nM) or saporin (10 nM-I mM) for 2, 6, 10, 24 and 48 h.
Cultures were pulsed with 1 pCi [3H]leucine for 2 h before harvest
onto glass fibre discs forcounting, exactly as described above.
HSB-2 cell outgrowth assay
The effects of four different molar concentrations (5.28 pM, 52.8
pM, 0.528 nM and 5.28 nM) of the 1-mer and 2-mer IT on HSB-2
cell proliferation in vitro was investigated. Approximately 105
HSB-2 cells were cultured in RIO medium in T25 culture flasks in
the continuous presence of a given molar concentration of IT.
Control cultures were grown in RIO medium only. Viable cell
counts were evaluated on a haemocytometer using trypan blue
exclusion at regular intervals.
HSB-2 human T-cell leukaemia in SCID mice
The behaviour and characteristics of the human T-cell acute
lymphoblastic leukaemia cell line HSB-2 in SCID mice has been
described previously (Morland et al, 1994). In the present study,
2 x 106 HSB-2 cells were injected i.v. into SCID mice via the tail
vein. This dose ofcells is known to lead to invariably fatal dissem-
inated leukaemia with a highly predictable clinical outcome
(Flavell et al, 1994).
HB2-SAP 1-mer and 2-mer toxicity in SCID mice
Groups of ten SCID mice (five male and five female in each
group) were injected via the tail vein with either the 1-mer or 2-
mer immunotoxin given at molar equivalent concentrations of 10
,ug (1-mer) or 11.58 [.g (2-mer). Each was given as a single dose,
or as two or three separate doses given on alternate days. Survival
ofanimals within each group was followed carefully over a 50-day
period and full post-mortems were carried out on animals dying
intercurrently.
Therapy protocol
Groups of ten SCID mice (five male and five female in each
group) were injected into the tail vein with 2 x 106 HSB-2 cells in
a 200-RI volume of RIO medium. Seven days following injection
of cells, animal groups received a single i.v. bolus injection (in a
200-[tl volume ofPBS) of molar equivalent amounts of either the
1-mer or 2-mer ITs, amounting to either 10 [.g of the 1-mer IT or
11.58 [xg of the 2-mer IT. Control groups received a mixture of
native HB2 antibody plus saporin (ateither a 1-meror 2-mermolar
equivalent ratio) or an injection of PBS alone (sham therapy
control group). Animals were inspected daily for signs of disease
(ruffled fur, weight loss and paraplegia being the principal clinical
signs). Animals found to be suffering unduly or that had become
moribund were killed painlessly, and full post-mortem examina-
tion of major organs (heart, lungs, brain, spleen, liver, kindeys,
adrenal glands, femurs) was carried out to confirm the presence of
disease. Similarly, animals found dead in cages were subjected to
full post-mortem examination.
Histopathology
All tissues were fixed in 10% neutral-buffered formol saline
(NBFS),processed and embedded in paraffin wax. Following fixa-
tion, femurs were decalcified in 5 mm EDTA. Sections of 5 itm
were cut and stained with haematoxylin and eosin (H and E) or
trypsinized and stained with the anti-CD43 monoclonal antibody
DFTl which specifically identifies human HSB-2 leukaemia cells
in paraffin-embedded tissue sections, as described previously
(Morland et al, 1994). A routine streptavidin-biotin detection
system was employed to detect antibody staining and sections
counterstained with haematoxylin.
Pharmacokinetics of 1-mer and 2-mer immunotoxins in
SCID mice
Two SCID mice,injected into the tail vein 7 days previously with 2
x 106 HSB-2 cells, received 50 .tg of either 1-mer or 2-mer IT in
PBS as a single bolus tail vein injection in a total volume of 100 xl.
Approximately 50 p1 ofblood was taken from the tail before injec-
tion with IT and 10 min, 1,2,4,6,8, 11,24,32 and48 h afterinjec-
tion. Blood was allowed to clot at room temperature, and serum
was separated by centrifugation and stored at-80°C until assayed.
IT concentrations in serum samples were quantified using a sensi-
tive capture-type enzyme-linked immunosorbent assay (ELISA).
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Figure 2 SDS-PAGE analysis undernon-reducing conditions on a5%~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ separating gel of HB2-Sap 1 -mer IT (track 1), HB2-Sap 2-mer IT(track2)~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ and native HB2 antibody (track3) gel stained with Coomasie blue~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Statistical evaluation~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Evlato 189.sttitial difrneieweteaygop a
car-ried out by Peto's log-rankanalysis using Solo SurvivalAnalysis~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ sotwr iBD)SaitclSfwr,LsAgls A S)
RESULTS
Elution of 1-mer and 2-mer HB2-Sap immunotoxins
from CM-sepharose and SDS-PAGE analysis
Figure 1 shows the elution profile of HB2-Sap 1-mer and 2-mer
ITs from CM-sepharose using a discontinuous linear gradient of
sodium chloride ranging from 0 to 300 mm. Fractions from three
regions ofthe elution peaks as indicated (I to III) were pooled and
subjected to non-reducing SDS-PAGE analysis, the results of
which are shown in Figure 2. Image analysis of detected bands
revealed that lane 1 (containing fractions comprising region II)
was composed of 84% 1-mer IT with molecular weight (MW) of
189.5 kDa, 12% free HB2 antibody (MW 160 kDa) and 4% conta-
minating 2-mer IT. Lane 2 (region III) contained approximately
92% 2-mer IT (MW 219 kDa), 5% contaminating 1-mer IT and
3% free HB2 antibody; while lane 3 (region I) contained >99%
native HB2 antibody with no detectable contaminating IT.
Binding of 1-mer and 2-mer HB2-Sap immunotoxins to
HSB-2 cells
The binding ofthree equimolar concentrations of 1-mer and 2-mer
HB2-Sap ITs and native HB2 antibody to HSB-2 leukaemia cells
was measured by flow cytometry and the mean fluorescent inten-
sity of staining obtained for each is presented in Table 1. The 1-
mer IT showed staining characteristics similar to those of native
HB2 antibody at all three equimolar concentrations studied. The 2-
mer IT, however, showed an overall reduced binding capacity for
HSB-2 cells, particularly pronounced at the subsaturating concen-
tration of 6.25 x 10-9 M for which the mean fluorescent intensity
obtained with 2-merIT was only approximately halfthat seen with
native HB2 antibody. To establish that this reduced binding
capacity of the 2-mer IT was due to an effect on the antigen
binding site and not on the binding capacity of the FITC-labelled
secondary reagent, we conducted a competitive inhibition experi-
ment, and the results we obtained are shown in Figure 3. The
results clearly show that the 1-mer IT competed with native HB2
antibody more effectively than the 2-mer, demonstrating unequiv-
ocally that the 1-mer IT had a higher binding affinity for CD7 on
the surface ofthe HSB-2 cell. This indicates that the reduced fluo-
rescent intensity observed for the 2-mer IT in the indirect fluores-
cent assay was indeed due to an effect on the antigen binding site.
Protein synthesis inhibition in HSB-2 cells by 1-mer
and 2-mer immunotoxins
The dose-dependent effects of 1-mer and 2-mer HB2-Sap ITs on
protein synthesis levels in HSB-2 leukaemia cells are shown in
Table 1 Mean fluorescence intensity of HSB-2 cells stained with equivalent molar concentrations of 1-mer and 2-mer HB2-Sap
immunotoxins or native HB2 antibody
Concentration (M) Mean fluorescence Intensity vs HSB-2 cells (arbitrary units)
1-mer IT 2-mer IT HB2 Ab BU12 Ab
6.25 x 10 1286 969 1234 10.8
6.25 x 10-9 965 573 1031 10.5
6.25x 10-10 198 155 126 12
a Irrelevant anti-CD19 antibody (isotype-matched control).
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Figure 3 Competitive inhibition of binding of FITC-labelled HB2 antibody to
HSB-2 cells with increasing molar concentrations of HB2-Sap 1 -mer (-) and
HB2-Sap 2-mer (0) ITs determined by flow cytometry
Concentration (M)
Figure 4 Inhibition of protein synthesis in HSB-2 target leukaemia cells by
HB2-Sap 1-mer (U) and 2-mer (0) ITs or by saporin alone (A). Error bars
represent one standard deviation
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Figure 5 Kinetics ofprotein synthesis inactivation in HSB-2 leukaemia cellsexposed to a range of 1-1132-Sap 1 -mer (A) or 2-mer (B) concentrations
(1O.-12 M-10-8 M) or to native saporin (C) (10-8 m-10--6 m). In some instances, the regression line was wasextrapolated beyond the 60-h time point to obtain the
tiol Regression coefficients obtained were as follows: A. 1-1132-Sap 1 -mer r = 0.928 (1"m), r = 0.925 (1" m), r = 0.913 (10-10m), r = 0.779 (10-11 m), r = 0.052
(10-12 m). B. 1-1132-Sap 2-mer r = 0.925 (10-8 m), r = 0.920 (10-9m), r = 0.921 (10-10 m, r = 0.929 (10-11 m), r = 0.849 (10-12M). C. Saporin r= 0.959 (1" m), r= 0.80
(10-7 m), r = 0.837 (10-8m). D. The tlo values (time in hours to reduce protein synthesis levels in treated cells to 10% ofthat seen in untreated control cells) for
each molar concentration were obtained from the rateslopes shown in A-C and plotted against concentration for 1 -mer (0), 2-mer (0) and saporin (A)
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Figure 6 Blocking of HB2-Sap 1-mer (U) and 2-mer (@) IT protein synthesis
inhibitory activity at a concentration of 1 x 10-10M fortarget HSB-2 cells by
increasing molar concentrations of native HB2 antibody. The effects of HB2
antibody alone without IT are also shown (A). Error bars represent one
standard deviation
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Figure 7 Outgrowth of HSB-2 cells exposed continuously to 5.28 pM of 1-
mer (0) or 2-mer (0) IT or to 5.28 nM) 1-mer (A) or 2-mer IT (A). Control
cultures (A) were grown in R10 medium only
Table 2 Pharmacokinetic parameters of 1-mer and 2-mer HB2-Sap immunotoxins in HSB-2 tumour-bearing SCID mice
Treatment Mouse no. t12 (a) t1(2) AUC Cl Vdss
(h) (h) (Rg mi-i h mg-' kg-') (ml h-' kg-') (ml kg-') (ml kg-')
HB2-Sap 1-mer 1 1.0 14 187 5.6 79 108
it 2 1.7 16 226 4.7 71 102
HB2-Sap 2-mer 3 4.7 30 282 4.7 70 142
it 4 3.9 36 450 2.9 75 135
AUC, area under the curve; CL, clearance; Vd' volume of distribution; SS, steady state.
100 - , The 1-mer or 2-mer IT had no significant effect on protein
i..__ synthesis levels above those seen with saporin alone in the CD7-
80 I- A cALL cell line NALM-6 (data not shown).
80 ^ ----___ ^ Experiments were conducted to measure the rate at which five
V- I different molar concentrations (10-12 m to 10-8M) of 1-mer and 2-
60 - , mer IT and three concentrations ofsaporin alone (10-8 M to 106 M)
inhibited protein synthesis in HSB-2 target cells. The rate slopes
-------------------------- expressed as a percentage of the control level of [3H]leucine
40 - uptake with respect to time obtained for HSB-2 cells treated with
each IT or saporin are shown in Figures 5A-C. The rate of inacti-
vation was clearly dose dependent and linear. The time taken for a 20- 1 log inhibition of protein synthesis relative to an equivalent
number of untreated control cells is defined as the t1o, and this
0 - valueplottedagainst each concentration of IT orsaporin is shown
0 10 20 30 40 50 inFigure SD. The datapresented in Figure 5D show that the 2-mer
Days IT consistently inactivated protein synthesis in HSB-2 cells more
Ire Ri iniivU, l of nnn-ti,mno ir-hon:rinn .rin mi;n Winwin.v/ ininrfinn rapidly than the 1-mer IT rivuiv o ouivivdi ui iiuii-tuiiluui-uuaritiy atiu unce i;t uiuwinlg i.v. §injeciion
with one (U), two (A), or three (V) 11.58-gg (52.8n M) doses of 2-mer HB2-
Sap IT
Figure 4. The 2-mer IT was 5.6 times more effective than the 1-
mer IT at inhibiting protein synthesis in HSB-2 target cells,
achieving its IC50 at a concentration of 4.1 x 10-12 M compared
with 2.3 x 10-11 M obtained with 1-mer IT. Saporin alone gave
an IC50 value of 2 x 10-7 M. The 1-mer IT was therefore 8696-fold
and the 2-mer IT 48 780-fold more effective than saporin alone.
Blocking of 1-mer and 2-mer immunotoxin protein
synthesis inhibitory activity for HSB-2 cells by HB2
antibody
Experiments were conducted to determine the concentrations of
native HB2 antibody required to block HB2-Sap 1-mer IT-and
2-mer IT-mediated protein synthesis inhibition in HSB-2 target
cells, and the results obtained are shown in Figure 6. On the basis
of the amount of native HB2 antibody required to reverse protein
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Table 3 Mean survival times of groups of HSB-2-challenged SCID mice
receiving therapy with 1 -mer or 2-mer HB2-Sap immunotoxins, HB2 antibody
plus saporin at a 1 -mer or 2-mer molarequivalent ratio or PBS sham treated
Group Therapy Mean survival Survivors
(days) at 295 days (%)
A HB2-Sap 2-mer IT 136.9 70
B HB2-Sap 1-mer IT 123.3 60
C HB2-sap Ab plus saporin 88.7 0
(2-merequivalent ratio)
D HB2 Ab plus saporin 83.8 10
(1 -merequivalent ratio)
E PBS sham treated 59.7 0
Days
Figure 9 Survival curves for groups of SCID mice following challenge with
2 x 106 HSB-2 leukaemia cells followed by therapy 7 days later with a single
i.v. injection of 52.8 nm (A) HB2-Sap 2-mer IT (--), (B) HB2-Sap 1 -mer IT
(--- -), (C) HB2 antibody plus saporin at a 2-mer equivalent ratio (---), (D) HB2
antibody plus saporin at a 1 -mer equivalent ratio (----) or (E) PBS sham
treated (-)
synthesis inhibition to half that seen in untreated controls (IC50),
the 2-mer IT required 3.7 times more antibody (1.1 x 10-8 M) than
the 1-mer IT (3 x 10-9 M) to achieve the same effect (Figure 6).
Total blockade of both 1-mer IT-and 2-mer IT-mediated cytotoxi-
city was only achieved at a gross excess antibody concentration of
10-7 M. Each IT was present in the assay system at a fixed concen-
tration of 1 x 10-10 M, and we can therefore conclude that a 1000-
fold molar excess of native HB2 antibody is required to
completely block IT cytotoxicity. Native HB2 antibody alone,
used over the same concentration range but without IT, had no
effect on protein synthesis levels (Figure 6).
Effects of HB2-Sap 1-mer and 2-mer ITs on HSB-2 cell
proliferation
The effects of four different equimolar concentrations of 1-mer or
2-mer IT on HSB-2 cell proliferation in vitro are shown in Figure
7. The 2-mer IT was more effective at inhibiting HSB-2 cell prolif-
eration than the 1-mer IT, delaying cell growth by several days.
Used over the same concentration range, neither I T had any effect
on the growth ofthe CD7- cell line NALM-6 (data not shown).
Pharmacokinetic profiles of 1-mer and 2-mer
immunotoxins
A two-compartment first-order pharmacokinetic model was used
to fit the 1-mer and 2-mer IT serum concentration data. The phar-
macokinetic parameters obtained for both the 1-mer and 2-mer ITs
in HSB-2 tumour-bearing SCID mice are shown in Table 2. It was
apparent that there was a very marked increase in the tl,2 (a) and t12
(,3) phases for the 2-IT and a resultant larger AUC for the 2-mer IT.
Toxicity of 1-mer and 2-mer ITs in SCID mice
All SCID mice receiving a single, double or triple i.v. 10-,ug dose
(52.8 nM) of 1-mer IT given on alternate days survived with no
apparent toxicological problems. In contrast, some animals
receiving molar equivalent doses of 2-mer IT encountered signifi-
cant toxicological problems. All animals receiving a single 11.58-
[ig dose (52.8 nM) of 2-mer IT survived, while only 80% and 50%
of animals receiving two and three doses, respectively, survived
(Figure 8). Post mortem and histopathological examination of
animals receiving 2-mer IT that died intercurrently revealed
varying degrees ofliverparenchymal cell necrosis and some renal
tubular necrosis; such lesions have been seen with saporin ITs in
mice previously (DJ Flavell,unpublished observations).
Therapeutic efficacy of HB2-Sap 1-mer and 2-mer
immunotoxins in HSB-2 leukaemia-bearing SCID mice
Survival curves obtained for groups of SCID HSB-2 mice treated
with a single 52.8-nM i.v. dose of 1-mer or 2-mer HB2-Sap ITs,
unconjugated HB2 antibody plus saporin or PBS sham treated are
shown in Figure 9, and the data is summarized in Table 3. The
presence of HSB-2 tumour growth was confirmed grossly and by
immunocytochemistry in all animals dying intercurrently during
the course ofthe study. There were no survivors in the PBS sham-
treated control group, all animals dying with disseminated
leukaemia by 92 days with a mean survival of 59.7 days. Animal
groups treated with 1-mer or 2-mer IT had mean survival times of
123.3 and 136.9 days, respectively, with a respective 60% and
70% of animals alive and disease-free in these groups on day 295
at the termination of the experiment. Treatment with native HB2
antibody plus saporin at two different ratios equivalent in molar
terms to 1-mer and 2-mer IT did have a therapeutic effect,
increasing mean survival to 83.8 and 88.7 days, respectively, with
only one animal from these groups surviving disease-free for the
duration of the study. Log-rank analysis revealed that the differ-
ences between the PBS sham-treated group and 1-mer IT-and 2-
mer IT-treated groups were highly significant (P=0.0316 and
P=0.0071 respectively). However, the difference between the 1-
mer and 2-mer IT therapy groups was not significant (P=0.6306).
The improved survival seen when a mixture of native HB2 anti-
body plus saporin was used at an equivalent 1-mer (but not 2-mer)
molar ratio wasjust significant when compared with sham-treated
controls (P=0.0573).
DISCUSSION
This work was undertaken to determine whether an anti-CD7-
saporin IT, HB2-Sap 2-mer, containing two saporin molecules per
antibody moleculeperformed bettertherapeutically in vivo against
the human CD7+ T-ALL cell line HSB-2 than HB2-SAP 1-mer IT
containing just one saporin molecule. We have clearly shown that
the 2-mer IT was more than five times more effective in vitro at
inhibiting protein synthesis in target HSB-2 cells than the 1-mer IT
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and that a proportionatly greater excess of native HB2 antibody
was required to block thecytotoxic activity of the 2-mer than was
required for the 1-mer IT. Similarly, other workers have described
similar increases in in vitro potency of ITs containing two toxin
molecules per unit antibody (Marsh and Neville, 1986; Ghetie et
al, 1993). In the present study, it was also clearly demonstrated
that the 2-mer IT inhibited in vitro HSB-2 cell proliferation more
effectively than the 1-mer IT. This improved in vitro performance
of the 2-mer IT occurred despite an apparent reduced binding
capacity of2-mer for HSB-2 cells as demonstratedby flow cytom-
etry. The flow cytometry data indicate that the reduced binding
capacity of the 2-mer IT is probably due to steric hindrance of
antigenbindingby the secondsaporinmoiety in aproportion of2-
mer immunotoxin molecules. This contention is further supported
by the observation that, in a competitive inhibition study, the 1-
mer IT had a higher binding affinity for CD7 than the 2-mer IT.
The apparent disparity that exists between the reduced binding
capacity of2-mer IT and yet the apparent increased in vitro effec-
tiveness over 1-mer IT atinhibiting bothproteinsynthesis and cell
proliferation in CD7+target cells may possibly beexplainedby an
improved internalization of the 2-mer IT to the appropriate intra-
cellular compartment. Perhaps, moresimply, theimproved in vitro
efficacy ofthe 2-mer IT may be an entirely numerical effect, with
the overall number of saporin molecules delivered per unit CD7
target moleculeovecompensating for the reducedbinding capacity
of this IT. In this respect, the relative high efficiency with which
the CD7 molecule is able to deliver saporin to the appropriate
cellular compartment is underscored by the very large 1000-fold
excess ofnative HB2antibody that isrequired to block both 1-mer
and 2-mer IT cytotoxicity in vitro. These data show that the rela-
tively small amount(12%) ofcontaminating native HB2 antibody
present in the 1-mer preparation therefore has an insignificant
effect on IT performance; and moreover our results indicate that
the reducedbindingcapacity ofthe 2-merIT may beinsufficient to
diminish the beneficialeffects ofdelivering twosaporin molecules
per unit CD7 target molecule. Such issues would likely be
resolved by quantifying the receptor-mediated endocytosis rates
for both the 1-mer and 2-mer ITs and by relating these to the
number of immunotoxin molecules bound at the cell surface.
Despite the improved in vitro performance of the 2-mer IT, the
therapeutic performance of 1-mer IT and 2-mer IT in the SCID
mouse model ofdisseminated HSB-2 leukaemia was almost iden-
tical, with the 2-mer ITperforming marginally though not signifi-
cantly better than the 1-mer IT.
Several workers have described the in vivotherapeutic efficacy
ofanti-CD7 ITsagainsthuman T-cellmalignancies (Fishwild etal,
1992; Jansen etal, 1992; Flavell etal, 1995a; Morland etal, 1994),
although all these studies have used immunotoxins composed of a
mixture ofITscontaining varied toxin -antibody ratios. Similar to
the present study, these studies have also demonstrated the in vivo
anti-tumour effects of native unconjugated anti-CD7 antibody,
which although pronounced are less significant than the thera-
peutic effects obtained when anti-CD7 ITs are used fortherapy. It
is assumed that SCID effector cells,particularly NK cells that are
still present in SCID mice (Dorshkind et al, 1985), areresponsible
for this anti-tumoureffect directedagainstantibody-coated tumour
cells, and we have recently made findings that strongly support
this contention (DJ Flavell et al, in preparation). Thus, it is true to
say that the in vivo anti-tumour effects seen in SCID mouse and
similar animal models of human T-ALL with anti-CD7 ITs in
realityrepresent aresponsetotwo different cytotoxic mechanisms.
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In order to determine the differential contribution that such diverse
cytotoxic mechanisms contribute to the eventual therapeutic
outcome, we are currently undertaking studies in NOD-SCID
mice, which are naturally deficient in NK cells.
The present study addressed the question ofboth in vitro and in
vivo immunotoxin potency in the context of the number of toxin
molecules carried by a single antibody molecule to a single
antigen unit on the target cell surface. The improved in vitro
performance of the 2-mer IT over the l-mer IT, despite the
reduced binding capacity of the 2-mer IT, is probably due to the
delivery of twice the number of saporin molecules per unit target
antigen and their resultant internalization by receptor-mediated
endocytosis to the appropriate intracellular compartment, as
discussed earlier. In addition to the 2-mer IT showing a demon-
strably improved IC50 over the 1-mer IT, kinetic studies also
revealed that the 2-mer IT inactivated protein synthesis in target
HSB-2 cells more rapidly than the 1-mer IT. We have described a
similar phenomenon previously with a combination of two bispe-
cific antibodies delivering saporin to HSB-2 cells via CD7 and
CD38 target molecules, resulting in a more rapid inactivation of
protein synthesis (Flavell et al, 1992). Although unproven, the
most likely explanation for this would seem to be that increasing
the overall number of toxin molecules delivered to and subse-
quently internalized by the target cell would increase the resultant
probability ofachieving a 'hit' on the target ribosome.
The finding that the increased in vitro potency of2-mer IT over
1-mer IT did not translate into an improved in vivo therapeutic
outcome in the SCID mouse model was disappointing. The 2-mer
IT was considerably more toxic in the SCID mouse than the 1-mer
IT, an observation that may possibly be explained by the greater
serum half-life of 2-mer IT. Myers et al (1995) have made similar
observations with an anti-CD19 immunotoxin (B43-PAP) in a
SCID mouse model of human cALL and were also able in this
instance to demonstrate that the IT species containing two PAP
molecules was significantly more effective therapeutically than
the single toxin-containing species. Ghetie et al (1995) undertook
studies based upon one ofour earlier reports (Flavell et al, 1995b)
and showed that an anti-CD19 immunotoxin containing two ricin
A chain toxin molecules perantibody molecule was more potent at
inactivating protein synthesis in target cell lines in vitro than an
equivalent IT containing just a single toxin molecule. However,
there was little difference between the therapeutic performance of
the one and two ricin A chain-containing ITs in a SCID-Daudi
mouse model of human lymphoma. An anti-CD25 IT containing
one or two ricin A-chain molecules performed almost identically
both in vitro and in vivo. In contrast, an anti-CD22 IT containing
two ricin A chain molecules per antibody molecule performed
significantly better than an equivalent single toxin containing IT
not only in vitro but also in vivo in the same SCID-Daudi model.
In sharp contrast to our own findings, these workers report that all
three of their two toxin-containing ITs were no more toxic in the
mouse than the one toxin-containing ITs. The reasons for this are
not clear, but it may reflect the greater sensitivity of the mouse to
the hepatic and renal toxicity ofsaporin.
It seems entirely possible that the properties and nature of the
target molecule dictate the therapeutic potency of a given IT
directed against this target. However, this alone cannot account for
the disparities that appear to exist between in vitro and in vivo IT
performance. Other issues, such as IT clearance rates from the
blood, accessibility of target cells by the IT and heterogeneity of
target antigen expression (Flavell et al, 1995a) by the target cells,
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are equally important factors that may have aprofound influence on
in vivo therapeutic efficacy. In the present study, the lack of
improvement may relate to in vivo tumour accessibility, which may
bereducedforthe 2-merITbecause ofits largermolecular size.The
2-mer IT, although more than 5 times more potent in vitro, also has
a demonstrably lower in vivo therapeutic index because of its
increased toxicity in the SCID mouse. While it was possible to
administer three 10-p.g doses ofthe 1-mer IT to SCID mice without
any attendanttoxicity, we wereonly able togive asingle 10-[tg dose
ofthe 2-merIT. This increased toxicity is almostcertainly due to the
increased serum half-life of the 2-mer IT and the resultant larger
AUC. Ghetie et al (1995),who did notfind any increased toxicity in
their two ricin A chain-containing ITs, did notprovide any pharma-
cokinetic data on these ITs, and it is therefore not possible to
comment on possible reasons for this in relation to our own find-
ings. We thus conclude that there would appear to be no therapeutic
advantage to be gained, at least in the presently described SCID
model of human T-ALL, in constructing ITs with more than one
saporin molecule linked to a single antibody molecule; indeed, the
increased toxicity that is observed is a major disadvantage.
However, the results of others suggest that different target mole-
cules anddifferent antibodies directed against the same target mole-
cule may behave differently. To this end, we are currently exploring
the in vivo therapeutic prformance of other 1-mer and 2-mer ITs
constructed with different anti-CD7, -CDl9, -CD22 and -CD38
antibodies, each with different epitope specificities.
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